You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 9,140,701

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,140,701

Title:	Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis
Abstract:	Compositions and methods are provided for prognostic classification of rheumatoid arthritis disease patients into subtypes, which subtypes are informative of the patient\'s need for therapy and responsiveness to a therapy of interest.
Inventor(s):	Robinson; William H. (Palo Alto, CA), Ho; Peggy Pui-Kay (Cupertino, CA), Zhao; Xiaoyan (Stanford, CA), Steinman; Lawrence M. (Stanford, CA)
Assignee:	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (Palo Alto, CA)
Application Number:	12/806,081
Patent Claims:	1. A method for the prognosis of the severity of rheumatoid arthritis in a human individual, the method comprising: detecting circulating immune complexes containing citrullinated fibrinogen and immunoglobulin in a sample of blood or derivative therefrom obtained from the individual; analyzing the fibrinogen immune complex content in said sample relative to a normal control by contacting the blood sample with C1q protein; contacting immune complexes bound to the C1q protein with an agent that selectively binds to fibrinogen; detecting the presence of a fibrinogen containing immune complexes; wherein the presence of said fibrinogen containing immune complexes, compared to a control sample, is indicative of positive binding; and providing an assessment of prognosis for said individual, where the presence of the immune complexes containing fibrinogen is indicative of a more severe disease prognosis. 2. The method of claim 1, wherein said agent selectively binds to fibrinogen is an antibody that specifically recognizes human fibrinogen. 3. The method of claim 1, wherein said immune complexes containing fibrinogen is predictive for response to a specific treatment, such as anti-TNF antibodies, CTLA4-Ig, rituximab, or anti-IL-6 antibodies. 4. The method of claim 1, wherein the human individual is a juvenile human, and the presence of the immune complexes containing fibrinogen is indicative of a disease phenotype associated with adult rheumatoid arthritis.

Details for Patent 9,140,701

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2029-08-18
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2029-08-18
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2029-08-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.